Chiesi Farmaceutici SpA has identified new D-3-phosphoglycerate dehydrogenase (3-PGDH; PHGDH) inhibitors for the treatment of idiopathic pulmonary fibrosis.
The University of Parma and the University of Modena and Reggio Emilia have jointly disclosed new transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
Work at Eikon Therapeutics Inc. has led to the discovery of new ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Recent patents from Vigil Neuroscience Inc. describe heterocyclic compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2) agonists.
Despite the increasing sophistication of anticancer therapies, many malignancies continue to evade treatment. T cells expressing chimeric antigen receptor (CAR) can effectively attack some tumors by recognizing antigens expressed on the tumor surface, but the therapy may prove ineffective if the target antigen is not abundant enough throughout the tumor.
Diabetic retinopathy (DR) is a leading cause of vision loss in patients with diabetes, with limited therapeutic options. While current treatments focus on the proliferative stage, there is an urgent need to understand the underlying mechanisms of the early stages of DR to halt progression. Growing research suggests that activated microglia are key drivers of inflammation in DR.
A team of researchers from the University of Castilla-La Mancha, Spain, further investigated the link between hippocampal G protein-activated inward rectifier potassium channel (GIRK) and Alzheimer’s disease pathology.
As of May 2023, the WHO recommends the use of a monovalent XBB.1 descendent lineage, such as omicron XBB.1.5, as the vaccine antigen for COVID-19 vaccines. However, BA.2.86 and its descendent lineages, such as JN.1, have emerged and rapidly spread worldwide.
Single agonists of the glucagon-like peptide-1 receptor (GLP-1R) have been a success in the treatment of obesity, but monomeric dual or triple agonists have demonstrated improved efficacy on energy intake, appetite or metabolic function.